BAVELLONI, A.; PIAZZI, M.; RAMAZZOTTI, G.; FIUME, R.; BLALOCK, W.; FAENZA, I. PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma. Italian Journal of Anatomy and Embryology, [S. l.], v. 122, n. 1, p. 21, 2017. Disponível em: https://oajournals.fupress.net/index.php/ijae/article/view/1730. Acesso em: 1 may. 2024.